GICS Sector : Healthcare
Viatris Inc.operates as a healthcare company worldwide.The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets.
Viatris Inc. reported a robust financial performance for 2025, with total revenues reaching $14.3 billion, representing a 2% growth versus 2024, excluding the India impact. The company's adjusted EBITDA stood at $4.2 billion. For the fourth quarter, total revenues were $3.7 billion, up 1% versus the prior year, driven by strong commercial performance across key regions. The actual EPS came out at $0.57, beating estimates of $0.532.
Publication Date: Mar -01
The company's financial guidance for 2026 is optimistic, with expected total revenue and adjusted EBITDA growth of approximately 2% versus 2025. Viatris anticipates new product revenues of $450 million–$550 million in 2026, which are expected to contribute to strong segment performance. Adjusted gross margins are expected to be modestly lower year-over-year due to anticipated losses of exclusivity and mix shift in the ARV business.
Viatris has identified opportunities to optimize its cost structure, improve resource allocation, and strengthen operational efficiency through an enterprise-wide strategic review. The company expects to deliver approximately $650 million in gross cost savings over a 3-year period, with $400 million in net savings. As Scott Smith mentioned, "we have identified opportunities to optimize our cost structure, improve our resource allocation, and strengthen our operational efficiency."
Analysts estimate next year's revenue growth at 1.8%. With a P/E Ratio of -4.9, the market has priced in challenging times for the company. However, the Dividend Yield stands at 3.22%, indicating an attractive return for income investors. The EV/EBITDA ratio is -76.6, suggesting that the company's enterprise value is not justified by its EBITDA. As Viatris focuses on in-market accretive growth assets and continues to optimize its cost structure, it may be able to drive growth in the short and medium term.
Viatris is actively pursuing business development opportunities, having completed 60 regional transactions in 2025, including the acquisition of Aculys Pharma in Japan. The company is expecting regulatory decisions for six product candidates in 2026 and is preparing for the launch of fast-acting meloxicam. With a robust pipeline and a commitment to shareholder return, Viatris is well-positioned for future growth.
Viatris Inc. (VTRS) Q4 2025 Earnings Call Transcript
Feb -26
Viatris Inc (VTRS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Initiatives
Feb -26
Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up
Feb -26
Viatris (VTRS) Surpasses Q4 Earnings and Revenue Estimates
Feb -26
Viatris (VTRS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Feb -26
Viatris forecasts 2026 profit below estimates on India manufacturing woes
Feb -26
Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results
Feb -26
Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend
Feb -26
Viatris Inc.'s brands with 3% growth are driven by increasing demand for generic and complex generics, expansion into emerging markets, and a strong product pipeline. Additionally, strategic partnerships, cost savings initiatives, and effective supply chain management contribute to their growth.
Viatris Inc.'s generics segment growth is driven by increasing demand for affordable medicines, patent expirations of blockbuster drugs, and strategic acquisitions. Additionally, the company's global presence, diversified product portfolio, and operational efficiencies contribute to its growth momentum.
Viatris offers a range of biosimilar products, which are highly similar to reference biologics, providing affordable and accessible treatment options for patients.
Viatris develops and commercializes complex generic products, including inhalers, injectables, and transdermal patches, offering cost-effective alternatives to branded products.
Viatris has a portfolio of branded products, including Wixela Inhub, a generic version of Advair Diskus, and Norvir, a protease inhibitor for HIV treatment.
Viatris offers a range of OTC products, including vitamins, minerals, and supplements, providing consumers with affordable healthcare solutions.
Viatris provides CDMO services, offering expertise in development, manufacturing, and packaging of pharmaceutical products.
Viatris Inc. faces moderate threat from substitutes due to the presence of alternative treatments and generic drugs in the market.
Viatris Inc. has a diverse customer base, which reduces the bargaining power of individual customers, making it a low threat.
Viatris Inc. relies on a few key suppliers for raw materials, which gives them some bargaining power, making it a moderate threat.
The pharmaceutical industry has high barriers to entry, including regulatory hurdles and significant capital requirements, making it a low threat for Viatris Inc.
The pharmaceutical industry is highly competitive, with many established players, making the intensity of rivalry a high threat for Viatris Inc.
| Value | |
|---|---|
| Debt Weight | 47.09% |
| Debt Cost | 9.58% |
| Equity Weight | 52.91% |
| Equity Cost | 9.58% |
| WACC | 9.58% |
| Leverage | 88.99% |
Value: 2.0
Growth: 9.3
Quality: 8.5
Yield: 0.0
Momentum: 8.5
Volatility: 6.7
1-Year Total Return ->
Value: 6.0
Growth: 7.1
Quality: 5.1
Yield: 0.0
Momentum: 10.0
Volatility: 3.7
1-Year Total Return ->
Value: 8.9
Growth: 2.0
Quality: 3.2
Yield: 7.0
Momentum: 3.0
Volatility: 7.0
1-Year Total Return ->
Value: 4.0
Growth: 9.0
Quality: 8.0
Yield: 0.0
Momentum: 5.5
Volatility: 2.7
1-Year Total Return ->
Value: 4.0
Growth: 3.7
Quality: 3.4
Yield: 0.0
Momentum: 8.5
Volatility: 5.7
1-Year Total Return ->
Value: 6.2
Growth: 6.0
Quality: 5.0
Yield: 0.0
Momentum: 6.0
Volatility: 1.0
1-Year Total Return ->